Socialised Pricing Programme in the Philippines

Partnership objective

Increase access to healthcare by developing a patient access program tailored to a patient’s ability to pay.

A socialised pricing program that considers the individual affordability level of a patient. A socialised pricing program that considers the individual affordability level of a patient. Copyright Roche

What are the health needs and challenges?

In the Philippines, there is limited public funding of healthcare and only a section of the working population have medical insurance plans through their employers. As a result, 57% of health expenses are out-of-pocket. The government-owned Philippine Healthcare Insurance Corporation (PhilHealth) provides basic national healthcare coverage, however, it doesn’t include biologic cancer treatment.

Biologics is a relatively new class of drugs that includes Herceptin (trastuzumab), a Roche targeted therapy for HER2-positive breast cancer.  It is estimated that only 6% of the relevant patients have access to innovative cancer therapy and adherence to full-course treatment remains a challenge.

Description of partnership activities and how they address needs and challenges:

The Roche Patient Access Programme was established to help people who are financially constrained, through a socialised pricing program that considers the individual affordability level of a patient. Physicians refer patients to the programme, who are then assessed by an independent third party for their ability to pay. Qualified patients receive a discount or free product for products like Herceptin, Avastin, MabThera, Perjeta, and Tarceva based on their financial status. This initiative pricing improves access to products for poorer patients without impacting the price for patients able to pay out of pocket.

In addition to these programmes, Roche Philippines is working with both national and local government units to mobilise funding for cancer patients 

Summary of impact and forward looking information:

By implementing the patient assistance programmes, the number of patients who are now able to access innovative cancer treatment has increased by 23% in 2015. Furthermore, the ability of patients to complete the full treatment duration has increased significantly.

Partnership information

Company(ies) Roche

Partner(s) Philam Life Insurance, PhiliHealth, Philippines Department of Health, Pru Life Insurance

Type of Partner(s) Government, NGOs, Other Business

Therapeutic Focus Non-Communicable Diseases, Women and Children's Health

Disease(s) Breast Cancer, Cancer, Women's Health

Program Type(s) Availability of Treatment - Differential Pricing, Prevention Programs - Awareness & Outreach

Targeted Population(s) Mothers, Patients in needs of treatment, People with low income, Women

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) Philippines

Start Date 2010

More information Roche Access to Healthcare

Anticipated completion date Ongoing